polatuzumab vedotin
Ligand Summary
Polatuzumab vedotin-piiq is a CD79b-directed antibody-drug conjugate with activity against dividing B cells. The small molecule, MMAE is an anti-mitotic agent covalently attached to the antibody via a cleavable linker. The monoclonal antibody binds to CD79b, a B-cell specific surface protein, which is a component of the B-cell receptor. Upon binding CD79b, polatuzumab vedotin-piiq is internalized, and the linker is cleaved by lysosomal proteases to enable intracellular delivery of MMAE. MMAE binds to microtubules and kills dividing cells by inhibiting cell division and inducing apoptosis
ChEMBL: CHEMBL3301582
DrugCentral: 5333
LyCHI: polatuzumab vedotin
Target Activities
10 Activities
Items per page:
10
1 – 10 of 10
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) | ||
---|---|---|---|---|---|---|
ANTIBODY BINDING | ||||||
BINDING AGENT | ||||||
BINDING AGENT | ||||||
BINDING AGENT | ||||||
BINDING AGENT | ||||||
BINDING AGENT | ||||||
BINDING AGENT | ||||||
BINDING AGENT | ||||||
BINDING AGENT | ||||||
BINDING AGENT | ||||||